Stay updated on KX2-361 Safety & PK in Refractory Malignancies Clinical Trial

Sign up to get notified when there's something new on the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the safety, tolerability, and pharmacokinetics of the drug KX2-361 in patients with advanced malignancies refractory to conventional therapies.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:25.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying inclusion and exclusion criteria related to health conditions, prior treatments, and other medical factors. Previously, this section had no information provided.
    Difference
    45%
    Check dated 2024-05-22T21:16:53.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:15:21.000Z thumbnail image

Stay in the know with updates to KX2-361 Safety & PK in Refractory Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page.